Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.

Autor: Vlasakakis G; Research and Development, GlaxoSmithKline, London, UK., Napolitano A; Research and Development, GlaxoSmithKline, London, UK., Barnard R; Research and Development, GlaxoSmithKline, London, UK., Brown K; Project Management, GlaxoSmithKline, London, UK., Bullman J; Research and Development, GlaxoSmithKline, London, UK., Inman D; Research and Development, GlaxoSmithKline, London, UK., Keymeulen B; Academic Hospital and Diabetes Research Center, Vrije Universiteit Brussel, Brussels, Belgium., Lanham D; Eurofins Pharma Bioanalysis Services UK Ltd., Leirens Q; SGS Exprimo NV, Generaal de Wittelaan 19A b5, B-2800, Mechelen, Belgium., MacDonald A; Oncology Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, Astrazeneca, Cambridge, UK., Mezzalana E; SGS Exprimo NV, Generaal de Wittelaan 19A b5, B-2800, Mechelen, Belgium., Page K; Research and Development, GlaxoSmithKline, London, UK., Patel M; Eurofins Pharma Bioanalysis Services UK Ltd., Savage CO; Research and Development, GlaxoSmithKline, London, UK., Zamuner S; Research and Development, GlaxoSmithKline, London, UK., van Maurik A; Research and Development, GlaxoSmithKline, London, UK.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2019 Apr; Vol. 85 (4), pp. 704-714. Date of Electronic Publication: 2019 Feb 05.

The Impact of the CB 2 Cannabinoid Receptor in Inflammatory Diseases: An Update.

Autor: Rakotoarivelo, Volatiana^1,2 (AUTHOR), Mayer, Thomas Z.^1,2,3 (AUTHOR), Simard, Mélissa^1,2 (AUTHOR), Flamand, Nicolas^1,2 (AUTHOR) nicolas.flamand@criucpq.ulaval.ca, Di Marzo, Vincenzo^1,2,3,4 (AUTHOR) nicolas.flamand@criucpq.ulaval.ca

Publikováno v: Molecules. Jul2024, Vol. 29 Issue 14, p3381. 36p.

Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality.

Autor: Carrascosa, Antonio J.¹ (AUTHOR) acarras3@hotmail.com, Navarrete, Francisco^2,3,4 (AUTHOR) fnavarrete@umh.es, Saldaña, Raquel¹ (AUTHOR) rasalca@gmail.com, García-Gutiérrez, María S.^2,3,4 (AUTHOR) maria.ggutierrez@umh.es, Montalbán, Belinda¹ (AUTHOR) belinda.montalban@gmail.com, Navarro, Daniela^2,3,4 (AUTHOR) dnavarro@umh.es, Gómez-Guijarro, Fernando M.¹ (AUTHOR) fernando_guijarro@yahoo.es, Gasparyan, Ani^2,3,4 (AUTHOR) agasparyan@umh.es, Murcia-Sánchez, Elena¹ (AUTHOR) emurcias@gmail.com, Torregrosa, Abraham B.^2,3,4 (AUTHOR) a.bailen@umh.es, Pérez-Doblado, Paloma¹ (AUTHOR) pdoblado1@hotmail.com, Gutiérrez, Luisa^2,3,4 (AUTHOR) luisa.gutierreze@umh.es, Manzanares, Jorge^2,3,4 (AUTHOR) jmanzanares@umh.es

Publikováno v: International Journal of Molecular Sciences. Jun2024, Vol. 25 Issue 11, p6268. 42p.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Autor: Meininger V; Ramsay Generale de Sante Hopital Prive Peupliers, Paris, France., Genge A; Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada., van den Berg LH; Department of Neurology, Brain Centre Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands., Robberecht W; KU Leuven, Department of Neurosciences, Experimental Neurology University Hospitals Leuven, Department of Neurology, Leuven, Belgium., Ludolph A; Department of Neurology, University of Ulm, Ulm, Germany., Chio A; Rita Levi Montalcini Department of Neuroscience, University of Turin, Turin, Italy., Kim SH; Department of Neurology, Hanyang University Medical Center, Seoul, South Korea., Leigh PN; Division of Medicine (Neurology), Trafford Centre for Biomedical Research, Brighton and Sussex Medical School, University of Sussex, East Sussex, UK., Kiernan MC; Brain & Mind Centre, Sydney Medical School, the University of Sydney, Sydney, NSW, Australia., Shefner JM; Barrow Neurological Institute, Phoenix, AZ, USA., Desnuelle C; Department of Neurology, University Hospital of Nice, Nice, France., Morrison KE; Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, UK; Faculty of Medicine, University of Southampton, University Hospital Southampton, Southampton, UK., Petri S; Department of Neurology, Hannover Medical School, Hannover, Germany., Boswell D; Neurosciences Therapy Area Unit, GlaxoSmithKline, Uxbridge, UK., Temple J; R&D Projects Clinical Platforms and Sciences, Quantitative Sciences, Clinical Statistics, GlaxoSmithKline, Uxbridge, UK., Mohindra R; Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge, UK., Davies M; Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge, UK., Bullman J; Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Stevenage, UK., Rees P; Neurosciences Therapy Area Unit, GlaxoSmithKline, Uxbridge, UK., Lavrov A; Neurosciences Therapy Area Unit, GlaxoSmithKline, Uxbridge, UK. Electronic address: arseniy.j.lavrov@gsk.com.

Publikováno v: The Lancet. Neurology [Lancet Neurol] 2017 Mar; Vol. 16 (3), pp. 208-216. Date of Electronic Publication: 2017 Jan 28.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.